[COMPANY_001] Institutes for BioMedical Research
LHW090
Clinical Trial Protocol CLHW090X2102
A two part randomized, double-blind, parallel-group, 
placebo-controlled study to evaluate the renal safety, 
tolerability and pharmacokinetics of LHW090 in patients 
with moderately impaired renal function on angiotensin 
receptor blockers
Document type: Amended Protocol Version
EUDRACT number: 2015 -004570 -15
Version number: v04 (Clean)Development phase: IIRelease date: 07-Aug-2017
Property of [COMPANY_001]
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of [COMPANY_001]Personal Data
[COMPANY_001] Confidential Page 2
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
Site Operations Manual (SOM)
A Site Operations Manual (SOM) accompanies this protocol, providing the operational details 
for study  conduct.
Notification of serious adverse events
Refer to Section 9.2 of the protocol for definitions and reporting requirements for Serious 
Adverse Events ( within 24 hours after awareness of the SAE to the local [COMPANY_001] Drug Safet y 
and Epi[INVESTIGATOR_647905] C linical Trial Leader. ).
Contact [CONTACT_647917].
[COMPANY_001] Confidential Page 3
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Table of contents
Site Operations Manual (SOM)........................................................................................... [ADDRESS_867757] of abbreviations .......................................................................................................... ..7
Pharmacokinetic definitions and symbols ........................................................................... 9
Protocol synopsis.............................................................................................................. .15
1 Introduction .................................................................................................................. .....18
1.1 Background............................................................................................................ 18
1.2 Study purpose ........................................................................................................ 23
2 Study objectives.............................................................................................................. ...23
2.1 Primary objective(s)............................................................................................... 23
2.2 Secondary objective(s)........................................................................................... 23
3 Investigational plan .......................................................................................................... .25
3.1 Study design........................................................................................................... 25
3.2 Rationale of study design....................................................................................... 27
3.3 Rationale of dose/regimen, duration of treatment ................................................. 28
3.4 Rationale for choice of comparator ....................................................................... 29
3.5 Purpose and timing of interim analyses/design adaptations.................................. 29
3.6 Risks and benefits.................................................................................................. 29
4 Population.................................................................................................................... ......30
4.1 Population.............................................................................................................. 30
4.2 Inclusion criteria .................................................................................................... 31
4.3 Exclusion criteria................................................................................................... 31
5 Restrictions for study subjects........................................................................................... 34
5.1 Contraception requirements................................................................................... 34
5.2 Prohibited treatment............................................................................................... 34
5.3 Dietary restricti ons and smoking........................................................................... 35Corporate Confidential Information
Corporate Confidential InformationCorporate Confidential Information
[COMPANY_001] Confidential Page 4
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
5.[ADDRESS_867758] demographics/other baseline characteristics............................................. 52
8.3 Efficacy / Pharmacodynamics ............................................................................... 52
8.4 Safety ..................................................................................................................... 52
8.4.1 Physical examination ............................................................................ 52
8.4.2 Vital signs.............................................................................................. 53
8.4.3 Height and weight ................................................................................. 53
8.4.4 Laboratory evaluations.......................................................................... 53
8.4.5 Electrocardiogram (ECG) ..................................................................... 54
8.4.6 Pregnancy and assessments of fertility ................................................. 54
8.5 Pharmacokinetics................................................................................................... 55
8.6 Other assessments.................................................................................................. 55
9 Safety m onitoring ............................................................................................................. .56
9.1 Adverse events....................................................................................................... 56Corporate Confidential Information
[COMPANY_001] Confidential Page 5
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
9.[ADDRESS_867759] demographics and other baseline characteristics...................................... 67
11.3 Treatments (study drug, rescue medication, other concomitant therapi[INVESTIGATOR_014], 
compliance)............................................................................................................ 67
11.4 Analysis of the primary variable(s) ....................................................................... 67
11.4.1 Variable(s)............................................................................................. 67
11.4.2 Statistical model, hypothesis, and method of analysis.......................... 67
11.4.3 Handling of missing values/censoring/discontinuations....................... 68
11.4.4 Supportive analyses............................................................................... 68
11.5 Analysis of secondary and exploratory variables .................................................. 69
11.5.1 Efficacy / Pharmacodynamics............................................................... 69
11.5.2 Safety..................................................................................................... 69
11.5.3 Pharmacokinetics .................................................................................. 70
11.5.5 Other assessments ................................................................................. 70
11.6 Sample size calculation.......................................................................................... 70
11 7 Power for analysis of key secondary variables 70
12 Ethical considerations....................................................................................................... .71
12.1 Regulatory and ethical compliance........................................................................ 71
12.2 Responsibilities of the investigator and IRB/IEC.................................................. 72Corporate Confidential Information
Corporate Confidential Information
[COMPANY_001] Confidential Page 6
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
12.3 Publication of study protocol and results............................................................... 72
13 Protocol adherence ........................................................................................................... .72
13.1 Protocol Amendments ........................................................................................... 72
14 References ................................................................................................................... ......74
15 Appendix 1: (Blinding table)............................................................................................. 75
16 Appendix 2: (ARB dosing)................................................................................................ [ADDRESS_867760] of tables
Table 8-1 Assessment Schedule, Part 1................................................................. 42
Table 8-2 Assessment schedule Part 2, Patients 1-16 ........................................... 46
Table 8-3 Assessment Schedule, Part 2 Patients 17 to 72, approximately............ 50
Table 9-1 Liver Event and Laboratory Trigger Definitions .................................. 60
Table 9-2 Follow Up Requirements for Liver Events and Laboratory Triggers ... 61
Table 9-3 Specific Renal Alert Criteria and Actions............................................. 63
Corporate Confidential Information
[COMPANY_001] Confidential Page 7
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
List of abbreviations
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
ARB angiotensin receptor blocker
ASL -MRI arterial spin labeling magnetic resonance imaging
AST aspartate aminotransferase
ANP atrial natriuretic peptide
b.i.d. twice a day
BMI Body Mass Index
CD-ROM compact disc – read onl y memory
CFR Code of Federal Regulation
CK creatinine kinase
CKD chronic kidney  disease
CRF Case Report/Record Form (paper or electronic)
CRI chronic renal insufficiency
CRO Contract Research Organization
CV coefficient of variation
EC Ethics committee
ECG Electrocardiogram
EDC Electronic Data Capture
eGFR Estimated Glomerular Filtration Rate
ELISA Enzy me-linked immunosorbent assay
FDA Food and Drug Administration
FIH first in human
GCP Good Clinical Practice
hr hour
HIV human immunodeficiency virus
ICHInternational Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IRB Institut ional Review Board
[COMPANY_001] Confidential Page 8
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
IRT Interactive Response Technology
LDH lactate deh ydrogenase
LLN lower limit of normal
mg milligram(s)
ml milliliter(s)
o.d. once a day
NEP neprily sin
p.o. oral
PA posteroanterior
PD pharmacod ynamic(s)
PK pharmacokinetic(s)
RBC red blood cell(s)
RBF renal blood flow
REB Research Ethics Board
RHT resistant hy pertension
SAE serious adverse event
SD standard deviation
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
TBL total bilirubin
ULN upper limit of normal
ULQ upper limit of quantification
WBC white blood cell(s)
[COMPANY_001] Confidential Page 9
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
Pharmacokinetic definitions and sy mbols
AUC0 -tThe area under the plasma concentration -time curve from time zero to time 't' 
where t is a defined time point after administration [ng x hr / mL ]
AUClastThe area under the plasma concentration -time curve from time zero to the time 
of the last quantifiable concentration [ng x hr / mL]
AUCtauThe area under the plasma concentration -time curve from time zero to the end 
of the dosing interval tau [ng x hr / mL ]
CmaxThe observed maximum plasma (or serum or blood) concentration following 
drug administration [ng / mL ]
Tmax The time to reach the maximum concentration after drug administration [hr]
[COMPANY_001] Confidential Page 10
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Corporate Confidential Information
[COMPANY_001] Confidential Page 11
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Corporate Confidential Information
[COMPANY_001] Confidential Page 12
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Corporate Confidential Information
[COMPANY_001] Confidential Page 13
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Corporate Confidential Information
[COMPANY_001] Confidential Page 14
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Corporate Confidential Information
[COMPANY_001] Confidential Page 15
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
Protocol sy nopsis
Protocol number LHW 090X2102
Title A two part randomized, double -blind, parallel -group, placebo -controlled study 
to evaluate the renal safety, tolerability and pharmacokinetics of LHW 090 in 
patients with moderately  impaired renal function on angiotensin receptor 
blockers
Brief title Study of the safety , tolerability, and pharmacokinetics of LHW 090 in patients 
with moderately impaired renal function
Sponsor and Clinical 
Phase[COMPANY_001]
Phase II
Intervention type Drug
Study typeInterventional 
Purpose and 
rationaleTo determine whether LHW 090 displays the clinical safety  profile to support 
further development in patients with moderately impaired renal function.
Primary Objective(s)Part 1: To assess the safety and tole rability of doses of LH W090 in patients 
with moderate renal impairment to inform design of Part 2.
Part 2:To assess the renal safety of LHW 090 in patients with moderate renal 
impairm ent.
Secondary 
ObjectivesAll Parts: To eva luate the pharmacokinetics of LH W090 and its active 
metabolite, LHV527, in patients with moderate renal impairment.
All Parts: To assess the safety  and tolerability of LHW 090 relative to placebo 
in patients with moderate renal impairment.
Study design This is a randomized, double -blind, parallel group, placebo -controlled study, 
in two sequential parts to evaluate the renal safety, tolerability and 
pharmacokinetics of LHW 090 in patients with moderately impaired renal 
function. 
Population Patients aged 40 to 85 (inclusive) with an estimated glomerular filtration rate 
(eGFR) between 30 and 59 mL/min/1.73m2at screening (inclusive) on a 
stable dose of an angiotensin receptor blocker (ARB) will be considered for 
this study.
Inclusion criteriaWritten infor med consent must be obtained before any assessment is 
performed.
Male and female patients, age 40 to 85 years of age (inclusive) on a 
stable (at least 1 month) dose of an angiotensin receptor blocker (ARB) 
and stable moderately impaired renal function, def ined here as an eGFR 
30-59 mL/min/1.73m2 (inclusive) using the [ADDRESS_867761] 3 months.
At screening, vital signs (systolic and diastolic blood pressure and pulse 
rate) will be assessed in the sitting position after the patient has rested 
for at least five minutes, and again after three minutes in the standing 
position. Sitting vital signs should be within the following ranges:
oral body temperature between 35.0- 37.5 °C
systolic blood pressure, 100 -170 mm Hg
diastolic blood pressure, 50- 100 mm Hg
pulse rate, 50 -95 bpm
[COMPANY_001] Confidential Page 16
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
Patients should be excluded if their standing vital signs (relative to 
sitting) show findings which, in the opi[INVESTIGATOR_689], are 
associated with clinical manifestation of postural h ypotension (i.e. 
absence of any other cause). The Investigator should carefully 
consider enrolling patients with either a > 20 mm Hg decrease in 
systolic or a >10 mm Hg decrease in diastolic blood pressure, 
accompanied by a > 20 bpm increase in heart-rate (comparing 
standing to sitting results).
Patients must weigh at least [ADDRESS_867762] a body mass index (BMI) within the range of 18 -40kg/m2. BMI = 
Body weight (kg) / [Height (m)]2.
Able to communicate well with the inve stigator, to understand and comply 
with the requirements of the study.
Exclusion criteriaHistory of angioedema, drug -related or otherwise, as reported by [CONTACT_4677].
Use of angiotensin converting enzy me inhibitors (ACE inhibitors), 
mineralocorticoid receptor antagonists (e.g. spi[INVESTIGATOR_571545]), aliskiren, vasopressin receptor antagonists (e.g. tolvaptan), 
or oral alkalinizing agents (e.g. sodium and potassium citrate or Shohl's 
solution).
Note: Patients who discontinue their ACE -inhibitor and substitute with 
an angiotensin receptor blocker (ARB) may be eligible to be re -
screened provided their medication regimen has been stable for at 
least [ADDRESS_867763] 3 
months. Any substitutions or changes to a patient's medication 
regimen must be done under the guidance of the patient's treating 
physician.
History of a renal transplant.
Known current significant left ventricular outflow obstruction, such as 
obstructive hypertrophic cardiom yopathy or signifi cant severe valvular 
disease on prior or current echocardiogram.
A serum potassium ≤ 3.5 mmol/l or ≥ 5. 5mmol/l at screening.
A previous history or previously diagnosed kidney  disorder which ,in the 
opi[INVESTIGATOR_689], may place the patient at hig her risk from 
his/her participation in the study or is likely to confound the interpretation 
of the study results. Such kidney disorders may  include renal cystic 
disease such as autosomal dominant polycystic kidney disease (histor y 
of an incidental asy mptomatic acquired renal cyst(s) is excepted); 
obstructive uropathy; renal stone(s) in the past 2 years; chronic interstitial 
nephropathy; drug -induced nephropathy; residual renal insufficiency 
following an epi[INVESTIGATOR_647906], septic shock or ischemic 
nephropathy; renal tubular acidosis requiring treatment; nephrotic 
syndrome or nephrotic range proteinuria; or renal artery stenosis.
Women of child- bearing potential, defined as all wom en physiologically 
capable of becoming pregnant.
Investigational and 
reference therapyLHW 090
Efficacy/PD 
assessmentsNot applicable
[COMPANY_001] Confidential Page 17
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Safety assessments!Vital signs
!Hematology
!Chemistry
!Urinalysis
!ECG evaluation
!Physical exam
!Columbia-Suicide Severity Rating Scale
!AE/SAEs
Other assessments!Pharmacokinetics
Data analysis A sample size of 12 patients (2:1 ac tive: placebo) will be considered for Part 
1 to assess the safety and tolerability.
A sample size of 72 patients (3 :3:2 high dose:low dose:placebo) will be 
considered for Part 2 to assess the changes in serum creatinine.
All data for vital signs, ECG evaluati ons, hematology, blood chemistry and 
urinalysis will be listed for each patient and summarized by [CONTACT_647918], treatment group, and for visit/ time interval where 
appropriate.
Summary tables with the number, percentage, and severity of adverse events 
will be provided to assess safety a nd tolerability per part and treatment 
group.
Proportion of patients change from baseline serum creatinine <0.3 mg/dL and 
≥ 0.3 mg/dL will be evaluated and summarized.
For Part 2, a Chi-square test will be performed to compare the proportion of 
patients who develop a renal event (a reproducible increase from baseline serum creatinine of ≥ 0.3 mg/dL confirmed on a repeat central laboratory
measurement within 24-48 hours) in the LHW090 and placebo groups. For this endpoint, baseline is defined as the average of all available pre-dose 
measurements coming from central laboratory results.
All PK  data will be listed and summarized by [CONTACT_14455], treatment, 
and visit/timepoint. 
Key words Moderate renal impairmentCorporate Confidential Information
Corporate Confidential Information
[COMPANY_001] Confidential Page 18
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
1 Introduction
1.1 Background
The adequate and timely control of blood pressure in patients diagnosed with hypertension is 
an important public health goal. Hypertension is a major risk factor for heart disease, kidney 
disease and stroke. Despi[INVESTIGATOR_647907], hypertension remains uncontrolled in more than 50% of patients ( Valderrama et al 2012 ). 
The phenomenon of resistant hypertension (RHT) was defined by [CONTACT_98076] 7 in 2003 as blood pressure that was uncontrolled despi[INVESTIGATOR_647908]-hypertensive agents, one of which is a diuretic ( Chobanian et al 2003 ). More recently, the European Society for 
Cardiology (ESC) and the joint American Society of Hypertension and the International Society of Hypertension (ASH/ISH) have issued similar definitions ( Mancia et al 2013 ; 
Weber et al 2014 ). Patients with RHT are more likely to display the sequelae of uncontrolled 
hypertension such as an enlarged heart or kidney damage. Depending on the population 
examined and the level of medical screening, it has been estimated that 5 to 30% of the 
hypertensive population may meet this definition ( James et al 2014 ); however, the prevalence 
is likely to rise with aging of the population and the increasing incidence of diabetes, obesity, and chronic kidney disease.
The natriuretic peptide (NP) family mediates  a wide-ranging number of potentially salutary 
effects on the heart, vasculature, kidney and other target tissues. The NP family is comprised of three structurally related peptide hormones-atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and C-type natriuretic peptide (CNP). ANP and BNP are primarily expressed in the heart and released by [CONTACT_647919]. Binding of natriuretic peptides to their r eceptors, NPR-A and NPR-B, activates a guanylate 
cyclase resulting in increased intracellular levels of cGMP. Physiologically, NPs have been 
shown to stimulate the excretion of sodium and water by [CONTACT_8212], induce relaxation of 
vascular smooth muscle cells, and have anti-fibrotic and anti-hypertrophic effects on the heart. ANP is largely degraded by a transmembrane endopeptidase called neprilysin (NEP) while a smaller fraction is removed from the circulation by [CONTACT_4639] a clearance receptor, NPR-C. Studies suggest that circulating levels of ANP can be increased by [CONTACT_647920]. Thus, NEP inhibitors are a potential therapeutic target for the treatment of hypertension. Clinically, NEP inhibitors given in combination with an angiotensin receptor blocker (ARB) have been shown to reduce blood pressure in patients with essential hypertension (Bavishi et al 2015 ). NEP inhibition in combination with an ARB may represent an attractive 
therapeutic option for patients with RHT.
 
 
 
Chronic kidney disease is 
recognized as a risk factor for resistant hypertension and it is estimated that 20-25% of patients with RHT have some degree of renal impairment ( Calhoun et al 2008 ). The purpose 
of the current study is to provide data on the clinical safety, tolerability and pharmacokinetics of 4 week dosing of LHW090 in patients with moderate renal impairment.
Corporate Confidential Information
[COMPANY_001] Confidential Page 19
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
1.1.[ADDRESS_867764] relevant data for the present study are summarized in the sections below. 
For detailed information, please refer to the Investigators Brochure.
Corporate Confidential Information
[COMPANY_001] Confidential Page 20
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Corporate Confidential Information
[COMPANY_001] Confidential Page 21
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Corporate Confidential Information
[COMPANY_001] Confidential Page 22
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Corporate Confidential Information
[COMPANY_001] Confidential Page 23
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
1.2 Study purpose
To determine whether LHW090 displays the clinical safety profile to support further 
development in patients with moderately impaired renal function.
2 Study objectives
2.1 Primary objective(s)
Primary objective(s) Endpoints related to primary objective(s)
!Part 1: To assess the safety and 
tolerability of doses of LHW090 in patients with moderate renal impairment to inform design of Part 2.
!Part 2: To assess the renal safety of 
LHW090 in patients with moderate renal 
impairment.!Part 1: Safety endpoints (including 
adverse events and serious adverse events) up to and including the EOS; plasma pharmacokinetic parameters, and serum creatinine
!Part 2: Proportion of patients who 
develop a renal event as defined by a 
≥0.3 mg/dL increase in serum creatinine 
from baseline
2.2 Secondary objective(s)
Secondary objective(s) Endpoints related to secondary objective(s)
!All Parts: To evaluate the 
pharmacokinetics of LHW090 and its active metabolite, LHV527, in patients with moderate renal impairment. !Plasma pharmacokinetic parameters 
(Cmax, Tmax, AUC)
!All Parts: To assess the safety and !Safety endpoints (including adverse Corporate Confidential Information
[COMPANY_001] Confidential Page 24
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
tolerability of LHW090 relative to 
placebo in patients with moderate renal impairment.events and serious adverse events) up to 
and including the EOS
Corporate Confidential Information
[COMPANY_001] Confidential Page 25
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
3 Investigational plan
3.1 Study design
This is a randomized, double-blind, parallel group, placebo-controlled study, in two sequential 
parts to evaluate the renal safety, tolerability  and pharmacokinetics of LHW090 in patients 
with moderately impaired renal function. Patients aged 40 to 85 (inclusive) with an estimated glomerular filtration rate (eGFR) between 30 and 59 mL/min/1.73m
2at screening (inclusive) 
on a stable dose of an angiotensin receptor blocker (ARB) will be considered for this study.
The study will be conducted in two parts. Part 1 will enroll a single cohort of 12 patients who 
will be randomized in a 2:[ADDRESS_867765] four day cycle, and then the dose will be escalated  once daily for the next four days and then  once daily for four days. If a renal event occurs during the treatment periods of the study or any of the individual stoppi[INVESTIGATOR_23893], then dosing will be stopped for that individual 
patient. For the purposes of this study, a renal event will be defined as a reproducible increase 
from baseline serum creatinine of ≥ 0.3 mg/dL confirmed on a repeat measurement within 
24-48 hours ( Mehta et al 2007 , Khwaja 2012 ). Throughout the study, any serum creatinine 
assessment that is increased ≥0.3 mg/dL compared to baseline will trigger a repeat assessment 
of serum creatinine after 24 hours to confirm whether criterion for a renal event is met.
Corporate Confidential InformationCorporate
Confidential
Information
Corporate Confidential Information
Corporate Confidential Information
[COMPANY_001] Confidential Page 26
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Part 1 is comprised of a screening period, a baseline period, a treatment period and an end of 
study evaluation. Patients who meet the eligibility criteria at screening will be domiciled on Day -2 for diet stabilization. Laboratory assessments performed at screening will be used to determine patient eligibility for the trial. On Da y -1, safety and baseline assessments of renal 
function  will be performed  
 Starting on Day 1, the patient 
will begin treatment with study drug or placebo, and dose will escalate two times for a total 
dosing period of 12 days. Pharmacokinetic  assessments will be collected as shown in the assessment schedule. After completing dosing, patients will be monitored for an additional 48 hours after which they will be discharged at the discretion of the investigator. The patient will be asked to return to the site approximately one week later for end of study assessments.
 
 
Part 2 will be double-blind and placebo-controlled to assess the safety and tolerability of 2 
dose levels of LHW090,  LHW090 once daily for 4 weeks. 
Approximately 72 patients will be enrolled in Part 2 and randomized in a 3:3:2 ratio to LHW090 and placebo. Therefore, in Part 2, approximately 27 patients are expected to be randomized to each of the active doses, and 18 patients are expected to be randomized to placebo. Randomization will be stratified by [CONTACT_647921] (see Appendix 2 ) at the 
time of enrollment. Patients who meet the eligibility criteria at screening will have baseline assessments of renal function (serum creatinine, urinalysis) collected on Day -[ADDRESS_867766] 7 days of dosing to ensure careful 
monitoring of renal function and pharmacokinetic parameters (see Table 8-3 ) On Day 7 at the 
investigator’s discretion, the patients will be released to complete the remaining 3 weeks of the treatment phase.Corporate Confidential InformationCorporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
[COMPANY_001] Confidential Page 27
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
3.2 Rationale of study design
The primary objective(s) of this study is to collect information pertaining to the safety 
(including renal safety) and tolerability of LHW090 in patients with moderate renal impairment.  
 
  
 
 
 
 
  
 
 
 
Chronic kidney 
disease (CKD) is a risk factor for the development of drug-related nephrotoxicity (Loghman-Adham et al 2012 ) 
 
 
 
 
A two part sequential design was chosen to assess the safety and tolerability of doses lower
than the expected therapeutic doses of LHW090 in renal patients before starting Part [ADDRESS_867767] dose so that renal function and PK can be closely monitored as the dose is escalated to the target dose. Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
[COMPANY_001] Confidential Page 28
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
In Part 2, 4 weeks dosing was chosen  
 to support future studies. 
Patients will be randomized in a 3:3:[ADDRESS_867768] 16patients in Part 2 will be domiciled beginning on Day -1 and until Day 7 so that renal function 
and PK can be closely monitored. On Day 7 at the investigator’s discretion, patients will be 
released to complete the remaining [ADDRESS_867769] double-blind design was chosen to enable earlier detection of any potential safety issues in Part 2 and to allow opportunities for adaptive changes if safety or tolerability issues arise. 
Since ARB therapy has been associated with increases in serum creatinine levels, which may 
be more pronounced in CKD patients; randomization for Part 2 will be stratified by [CONTACT_647921]--"low" versus "usual" as described in Appendix 2 in order to balance the influence of 
ARB dose on serum creatinine. A cross-over design was not considered in order to minimize 
the potential for carry-over effects. A double-blind study was chosen to reduce bias.
3.3 Rationale of dose/regimen, duration of treatment
In Part 1, patients will receive escalating doses of LHW090  with each dose administered once daily for four days.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 The pharmacokinetics of LHW090 
and LHV527  is anticipated to be similar between Parts 1 and 2. Likewise, after the domiciling period for Part 2, LHW090  pharmacokinetics of LHW090 and LHV527 are also anticipated to be similar at the end of Part 2 (i.e., day 28). Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
[COMPANY_001] Confidential Page 29
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
In Part 2, importantly, although the proposed doses of LHW090 are  once 
daily, pending evaluation of data from Part 1, a lower dose may be studied  
 
 
3.4 Rationale for choice of comparator
In this study, the comparator will be placebo in order to evaluate the effects of LHW090 in patients with moderate renal impairment on angiotensin receptor blocker therapy without interference by [CONTACT_647922].
3.6 Risks and benefits
There is no benefit expected for subjects participating in this study.In Part 1, patients will receive escalating doses of LHW090  over four days.  
 
   
   
 
 
 
 
  
  Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
[COMPANY_001] Confidential Page 30
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
 
  
  
 
 
 Based on other compounds with a 
similar mode of action, low blood pressure may be a potential risk.  
 
An allergic-type reaction called angioedema has been reported with a compound with a 
similar mode of action as LHW090. This risk may be increased when LHW090 is taken concomitantly with an ACE inhibitor. Subjects  who are unable to substitute an ACE inhibitor
with an angiotensin receptor blocker are excluded from this study. Due to the potential for pharmacokinetic drug-drug interactions, subjects taking statins should be monitored for 
statin-related myopathy during the duration of the study. For further details, refer to the 
Investigator Brochure and Section 5.2 “Prohibited treatment”.
The risk to subjects in this trial will be minimized by [CONTACT_297213], 
individual and study stoppi[INVESTIGATOR_3418], and close clinical monitoring. Clinical monitoring includes regular monitoring of renal function in an in-patient setting in Part 1.  
 
 
In Part 1, a maximum of [ADDRESS_867770] as part of the study. 
Additional samples for monitoring of any safety findings would be in addition to this. This is not considered to be a risk for this population.
There may be unknown risks of LHW090 which may be serious and unforeseen.
4 Population
4.1 Population
The study population will be comprised of patients aged 40 to 85 (inclusive) on a stable dose 
of an ARB with stable (at least 3 months) moderately impaired renal function defined here as an eGFR of 30-59 mL/min/1.73m2 (inclusive).
For the purposes of this trial, eGFR will be calculated using the [ADDRESS_867771] Study 
equation as follows ( Levey et al 2006 ): estimated GFR = 175 × (Scr)
-1.154× (Age)-0.203× 
(0.742 if female) × (1.212 if African American) where Scr is serum creatinine in mg/dL.
For Part 1, a cohort of 12 patients will be enrolled and randomized. For Part 2, a total of 
approximately 72 patients will be enrolled and randomized.Corporate Confidential Information
Corporate Confidential 
Information
Corporate Confidential Information
[COMPANY_001] Confidential Page 31
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
Description for population (Part 1, Part 2)
4.[ADDRESS_867772] be obtained before any  assessment is performed.
If consent cannot be expressed in writ ing, it must be formally documented and 
witnessed, ideally via an independent trusted witness.
2.Male patients and female patients without childbearing potential, age 40 to 85 y ears of age 
(inclusive) on a stable (at least 1 month) dose of an angiotensin rec eptor blocker (ARB) 
and stable moderately impaired renal function, defined here as an eGFR 30 -59 
mL/min/1.73m2 (inclusive) using the [ADDRESS_867773] 
3months.
3.At screening, vital signs (sy stolic and diastolic blood pressure and pulse rate) will be 
assessed in the sitting position after the patient has rested for at least five minutes and 
again after three minutes in the standing position. Sitting vital signs should be within the 
following ranges:
oral bod y temperature between 35.0-37.5 °C
systolic blood pressure, 100- 170 mm Hg
diastolic blood pressure, 50- 100 mm Hg
pulse rate, 50 - 95 bpm
Patients should be excluded if their standing vital signs (relative to sitting) show findings 
which, in the opi[INVESTIGATOR_689], are associated with clinical manifestation of 
postural hy potension (i.e. absence of any  other cause). The Investigator should carefully  
consider enrolling patients with either a > 20 mm H g decrease in s ystolic or a >10 mm Hg 
decrease in diastolic blood pressur e, accompanied by  a > 20 bpm increase in heart- rate 
(comparing standing to sitting results).
4.Patients must weigh at least [ADDRESS_867774] a body  mass 
index (BMI) within the range of 18 - 40 kg/m2. BMI  = Bod y weight (kg) / [ Height (m)]2.
5.Able to communicate well with the investigator, to understand and comply with the 
requirements of the study.
4.[ADDRESS_867775] has returned to baseline, whichever is longer; 
or longer if required b y local regulations.
2.History  of hy persensitivity to any  of the study  drugs or to drugs o f similar chemical classes .
3.History  of angioedema, drug -related or otherwise, as reported b y the patient.
4.Use of angiotensin converting enz yme inhibitors (ACE inhibitors), mineralocorticoid 
receptor antagonists (e.g. spi[INVESTIGATOR_256813]), aliskiren, vasopressin receptor 
antagonists (e.g. tolvaptan), or oral alkalinizing agents (e.g. sodium and potassium citrate 
or Shohl's solution).
Note: Patients who discontinue their ACE- inhibitor and substitute with an angiotensin 
receptor blocker (ARB) may  be eligible to be re -screened provided their medication 
regimen has been stable for at least 1 month and their renal function has been stable for at 
[COMPANY_001] Confidential Page 32
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
least 3 months. Any  substitutions or changes to a patient's medication regimen must be 
done under the guidance of the patient's treating phy sician.
5.History  of a renal transplant.
6.Known current significant left ventricular outflow obstruction, such as obstructive 
hypertrophic cardiom yopathy or significant severe valvular disease on prior or current 
echocardiogram.
7.A history  of clinicall y significant ECG abnormalities, as determined b y the Inves tigator, 
or an y of the following ECG abnormalities at screening:
QTcF > 480 msec
8.Known history  or current clinically  significant arrhy thmias.
9.History  within the previous 6 months of my ocardial infarction, coronary  artery  by[CONTACT_4660] (CABG), percutaneous c oronary  intervention (PCI ), stroke, transient ischemic attack 
(TIA) or acute kidney  injury .
10. Hemoglobin levels below 9.0 g/dL at screening.
11.A serum potassium ≤ 3.5 mmol/l or ≥ 5. 5 mmol/l at screening.
12.A previous history  or previously  diagnosed kidney disord erwhich ,in the opi[INVESTIGATOR_684], may  place the patient at higher risk from his/her participation in the study or 
is likely  to confound the interpretation of the study  results. Such kidney  disorders may  
include renal cy stic disease such as autosomal dominant poly cystic kidney disease (history  
of an incidental asy mptomatic acquired renal cy st(s) is excepted); obstructive uropathy ; 
renal stone(s) in the past 2 years; chronic interstitial nephropathy ; drug -induced 
nephropath y; residual renal in sufficiency  following an epi[INVESTIGATOR_647909], septic shock or ischemic 
nephropath y; renal tubular acidosis requiring treatment; nephrotic sy ndrome or nephrotic 
range proteinuria; o r renal artery  stenosis.
13.Donation or loss of 400 mL  or more of blood within 8 weeks prior to initial dosing, or 
longer if required b y local regulations.
14.Significant illness which has not resolved within two (2) weeks prior to initial dosing.
15.History  of imm unodeficiency  diseases, including a positive HIV  test result.
16.A positive Hepatitis B surface antigen or Hepatitis C test result.
17.History  of malignancy  of any  organ s ystem (other than localized basal cell carcinoma of 
the skin), treated or untreated, within the past 5 y ears, regardless of whether there is 
evidence of local recurrence or metastases.
18. Pregnant or nursing (lactating) women.
19.Women of child- bearing potential, defined as all women phy siologically  capable of 
becoming pregnant .
Women are consi dered post -menopausal and not of child bearing potential if they  have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g. age appropriate, history  of vasomotor s ymptoms), total hy sterectom y or have had 
surgical bila teral oophorectomy  (with or without hy sterectom y) or tubal ligation at least 
six weeks ago. In the case of oophorectomy  alone, only  when the reproductive status of 
the woman has been confirmed by  [CONTACT_50085]. 
[COMPANY_001] Confidential Page 33
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
20.Sexually  active males unwilling to use a condom during intercou rse while taking drug and 
for 2 weeks after stoppi[INVESTIGATOR_105762] y medication. A condom is required for all sexually  active 
male participants to prevent them from fathering a child AND to prevent delivery  of the 
investigational drug via seminal fluid to their sexual partner. In addition, male participants 
should not donate sperm for the time period specified above.
21.On the Columbia -Suicide Severity  Rating Scale, score “yes” on item [ADDRESS_867776] 6 months, or 
“yes” on any  item of the Suicidal Behavior section, except for the “Non-Suicidal- Self 
Injurious Behavior” (question also included in the Sui cidal Behavior section), if this 
behavior occurred in the past [ADDRESS_867777] the 
patient at higher risk from his/her participation in the study , or is likel y to prevent the 
patient from compl ying with the requirements of the study  or completing the study .
Subset of patients in MRI substud y (Part 2), inclusion/exclusion criteria:
1.Patients with contraindications to MRI , including:
Brain aneury sm clip
Implanted neural stimulator
Implanted cardiac pacemaker or defibrillator, or presence of intracardiac wires
Prosthetic heart valves
Cochlear implant
Ocula r foreign bodies that might be ferromagnetic (e.g., metal shavings)
Other implanted medical devices (e.g., insulin pumps)
Metal shrapnel or bullets still in the body
Severe claustrophobia
Tattoos (as determined by  [CONTACT_11219] I mager)
Weight in excess of MRI machine capacit y
Note: I n the case where a safety laboratory assessment at screening is outside of the range 
specified above, the assessment may  be repeated once prior to randomization. If the repeat 
value remains outside of the specified ra nges, the subject is excluded from the study .
No additional exclusions may  be applied by  [CONTACT_093], in order to ensure that the study  
population will be representative of all eligible patients.
[COMPANY_001] Confidential Page 34
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
5 Restrictions for study subjects
During recruitment, screening/informed consent review, and baseline visit, the subjects must 
be informed and reminded of the following restrictions:
5.1 Contraception requirements
Not applicable. Onl y women of non- childbearing potential will be included in this study .
5.2 Prohibited treatment
Use of the following medications is not allowed during the course of the study  from screening 
(Visit 1) to the end of the study . Patients who are receiving such medication(s) will be 
excluded, or if ethically  and clinicall y justified, the medicat ion(s) should be gradually 
withdrawn at least seven day s before Visit 2:
ACE inhibitors, mineralocorticoid receptor antagonists (e.g. spi[INVESTIGATOR_256813]), 
aliskiren, vasopressin receptor antagonists (e.g. tolvaptan), or oral alkalinizing agents ( e.g. 
sodium and potassium citrate or Shohl's solution)
oNote: Patients who discontinue their ACE- inhibitor and substitute with an 
angiotensin receptor blocker (ARB) may  be eligible to be re -screened provided their 
medication regimen has been stable for at least [ADDRESS_867778] 3 months. 
Chronic administration (defined as >3 day s per week) of NSAIDs or COX- [ADDRESS_867779] not be within 48 hours prior to an y scheduled visit or 
assessment or serum creatinine.
Use of other investigational drugs at screening or within 30 days or 5 half -lives of the drug 
at screening, whichever is longer, unless local health authority  guidelines mandate a 
longer period.
Treatment with an y medication that is contraindicated in renally  impaired patients
IV contrast d yes such as that used for a radiologic procedure
Recombinant human ery thropoietin
The following medications are prohibited due to potential for pharmacokinetic drug-drug 
interactions: bupropi[INVESTIGATOR_2394], efavirenz, ifosfamide (sensitive CYP2B6 substrates); amodiaquine, 
paclitaxel, pi[INVESTIGATOR_051], repaglinide (sensitive CYP2C8 substrates); celecoxib, glimepi[INVESTIGATOR_14956], 
pheny toin, warfarin (sensitive or narrow index CYP2C9 substrates); glyburide (CYP2C9 and 
OATP1B1 substrate); irinotecan (OATP1B1 & BCRP substrate); topotecan (BCRP substrate);
methotrexate (OAT1/3, BCRP substrate), bosentan (OATP1B1 substrate), atazanavir, 
cyclosporine, eltrombopag, gemfibrozil, lopi[INVESTIGATOR_054], rifampin, ritonavir, saquinavir, tipranavir 
(OATP1B1/1B3 inhibitors); cimetidine, diclofenac, probenecid (OAT1/3 inhibitor) .
[COMPANY_001] Confidential Page 35
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
All other prior non-study  medications (not specifically  contraindicated in the exclusion 
criteria) will be allowed, provided the patient has been on a standard treatment regimen 
(atleast 4 weeks of the same dose) and the treatment is not planned to be changed during the 
course of the study .
5.3 Dietary  restrictions and smoking
In Part 1, no alcohol is permitted from the domiciling period until after Study  Completion 
evaluation. In Part 2, no alcohol will be permitted during the domiciling period and 
starting 24 hours prior to and during study  visits.
Intake of xanthine (e.g. caffeine) containing food or beverages (i.e., coffee, tea, soda, 
chocolate) will be restricted to no more than 2 cups/day .
Subjects can drink water ad libitum . To ensure adequate h ydratio n for urine collections in 
Part [ADDRESS_867780] 240 mL every  4hours 
during waking hours in addition to fluid taken with meals and medication.
Subjects should be counseled to avoid consuming large portions of cooked meat in the 
24hours prior to laboratory  assessments. This restriction will reduce the variability  in 
serum creatinine assessments which can be falsely elevated by [CONTACT_647923]. 
During the domiciling period in Part 1 and Part 2, meals will be outlined by [CONTACT_647924]’s dietician in accordance with nutritional guidelines for patie nts with chronic 
kidney  disease and nutritional counseling from the subject’s phy sician.
Subjects will follow a standard weight maintaining diet while domiciled. No food other than 
that specified in the protocol will be consumed at any time during confinement. 
Subjects should be advised to consume the entire contents of the meal provided.
Meals should be provided only after all study  procedures including blood and urine 
collections scheduled for that time have been completed.
A copy  of the diet with content and nutritional information (amount of protein, carbohy drates, 
fat and calories for each meal) will be provided to the Sponsor prior to study  start upon 
request.
5.4 General restrictions
In Part 1, no strenuous phy sical exercise (e.g. weight training, aerobics, football) for 
7days prior to dosing until after Study  Completion evaluation.
In Part 2, no strenuous phy sical exercise (e.g. weight trai ning, aerobics, footbal l) for 
7days prior to dosing until after Study  Completion evaluation, particularl y for the 
48hours prior to study  visits.
[COMPANY_001] Confidential Page 36
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
6 Treatment
6.1 Study treatment
Details on the storage and management of study medication, randomization and instructions 
for prescribing and taking study treatment are outlined in Section 3 of the Site Operations Manual.
6.1.1 Investigational treatment
The Investigational drug LHW090  matching placebos will be 
prepared by [CONTACT_553518] i nvestigator site as open labelled bulk supply for 
Part 1.
For Part 2, LHW090 and its matching placebo will be supplied as double blind patient packs.
6.2 Treatment arms
Part 1 : Subjects will be assigned to one of the following 2 treatment arms in a ratio of 2:1:
!A: LHW090  daily for 4 days, followed by  4 days followed by 
 4 days
!B: Matching placebo
Part 2 : Subjects will be assigned to one of the following LHW090 treatment arms or placebo 
in a ratio of 3:3:2:
!A: LHW090  once daily
!B: LHW090  once daily
!C: Matching placebo
6.[ADDRESS_867781] 3 days prior to the ne xt study visit. A drug interruption occurring for 
≥4 consecutive days or ≥[ADDRESS_867782] dose of ACE inhibitor. Consideration should also be given to the existing ARB treatment of subjects in the study; concomitant treatment with an ACE inhibitor and an ARB should be avoided according to current guidelines and in compliance with the applicable local prescribing information of renin angiotensin aldosterone system (RAAS) agents.Corporate Confidential Information
[COMPANY_001] Confidential Page 37
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
6.4 Treatment assignment
Randomization numbers will be assigned in ascending, sequential order to eligible subjects 
(see Site Operations Manual for details). The investigator will enter the randomi zation 
number on the CRF.
In Part 1, randomization numbers will be generated using the following procedure to ensure 
that treatment assignment is unbiased and concealed from subjects and investigator staff. 
Arandomization list will be produced by [CONTACT_121922] y 
Management, using a validated system that automates the random assignment of treatment 
arms to randomization numbers in the specified ratio. The randomization scheme for subjects 
will be reviewed and approved b y a member of the [COMPANY_001] Randomization Group.
In Part 2, at Visit 2, all eligible subjects will be randomized via Interactive Response 
Technology  (IRT) to one of the treatment arms. The investigator or his/her delegate will 
contact [CONTACT_647925]/exclusion criteria. 
TheIRT will assign a randomization number to the subject, which will be used to link the 
subject to a treatment arm and will specify  a unique medication number for the first package 
of investiga tional treatment to be dispensed to the subject.
A subject randomization list will be produced by [CONTACT_6609] a validated system 
that automates the random assignment of treatment arms to randomization numbers. Once a 
patient is deemed eligible for enrollment into the study  and ready for dosing, the next lowest 
available randomization number will be assigned. These randomization numbers are linked to 
the different treatment arms, which in turn are linked to medication numbers. A separate 
medicatio n list will be produced b y or under the responsibility  of [COMPANY_001] Drug Supply .
Management using a validated system that automates the random assignment of medication 
numbers to packs containing the investigational drug(s).
6.[ADDRESS_867783] double -blind study : subjects, investigator staff, 
and persons performing the assessments will remain blind to the identity  of study  treatments 
according to the specifications provided in Appendix 1.
The identity  of the treatments will be concealed by [CONTACT_50090], labeling, schedule of administration, appearance, and odor.
Randomization data are kept strictly  confidential , and are accessible only to authorized 
personnel (e.g. unblinded site staff (pharmacist or authorized designee at the site), unblinded 
sponsor staff (e.g. for drug resuppl y, unblinded monitor), and s ample analysts), until 
unblinding of the trial as described in the table in the blinding table in Appendix 1.
The study  statistician, the study  programmer and other personnel involved in data analysis 
(e.g. biomarker expert) will have access to the randomizat ion list for planned and unplanned 
interim analy ses, and are allowed to share unblinded information with the rest of the clinical 
team as appropriate for internal decision purposes, as outlined in the blinding table in 
Appendix 1.
[COMPANY_001] Confidential Page 38
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Unblinding will occur in the case of patient emergencies (see Section 6.6 ), at the time of the 
interim analysis and at the conclusion of the study.
6.[ADDRESS_867784] who presents with an emergency condition. A complete set of emergency code break cards will be provided to the investigator site(s) and a complete set will be available at [COMPANY_001] for Part [ADDRESS_867785], with the details of drug treatment covered by a removable, scratch-off cover. In an emergency, the scratch-off cover can be 
removed to determine the treatment. The scratch-off covers are not to be removed for any reason other than an emergency. When the inve stigator removes the scratch-off cover he/she 
must note the date, time, and reason for removing it and retain this information with the case report form documentation. The unblinded treatment code should not be recorded on the 
CRF. The investigator must also immediately inform the [COMPANY_001] local monitor that the code 
has been broken.
For Part 2, emergency code breaks are performed using the IRT. When the investigator 
contacts the IRT to unblind a patient, he/she must provide the requested patient identifying 
information and confirm the necessity to unblind the patient. The investigator will then 
receive details of the drug treatment for the specified patient and a fax confirming this information. The system will automatically inform the [COMPANY_001] monitor for the site and the Clinical Trial Head that the code has been broken.
It is the investigator’s responsibility to ensure that there is a procedure in place to allow access 
to the IRT/code break cards in case of emergency. If appropriate, the investigator will inform the subject how to contact [CONTACT_5657]/her backup in cases of emergency when he/she is unavailable.
An assessment will be done by [CONTACT_647926] a given subject and, if applicable, whether the subject can continue into the next trial phase (e.g., an 
unblinded extension).
6.7 Treatment exposure and compliance
Pharmacokinetic parameters (measures of treatment exposure) will be determined in all 
subjects treated with LHW090, as detailed in Section 8.5 .Corporate Confidential Information
[COMPANY_001] Confidential Page 39
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
6.8 Recommended treatment of adverse events
Adverse events should be treated at the discretion of the Investigator based on his/her 
judgment and best medical practices. Medication used to treat AEs must be recorded on the 
Concomitant medications/Significant non -drug therapi[INVESTIGATOR_50061].
6.[ADDRESS_867786] be recorded on the 
Concomit ant medications/Significant non -drug therapi[INVESTIGATOR_430322].
6.10 Concomitant treatment
All prescription medications, over-the-counter drugs, herbal medications and significant 
non-drug therapi[INVESTIGATOR_014] (including physical therapy  and blood transfusions) taken within the 
timeframe defined in the entry criteria prior to the start of the study  and during the study , must 
be recorded on the Concomitant Medications/Non -drug therapi[INVESTIGATOR_647910].
Certain prescription, over-the-counter or herbal medicat ions will not be allowed during the 
course of the study  unless the patient has been on a standard treatment regimen for at least 
30days prior to first dosing and will continue their regular regimen without changes 
throughout the study  (unless required to treat adverse events). Some of these medications ma y 
have to be discontinued, as per discussion with the sponsor. Please refer to Section 5.2 for 
prohibited treatments.
Due to the potential for pharmacokine tic drug -drug interactions, subjects taking statins should 
be monitored for statin -related myositis (e.g. muscle pain or elevations in creatinine kinase) 
during the duration of the study . Under the guidance of their treating physician, subjects on 
rosuvast atin may consider halving their dose or switching to another statin for the duration of 
the study .
The investigator should instruct the patient to notify  the study  site about any  new medications 
(prescription or over-the-counter) he/she takes after the start of the study drug. Medication 
entries should be specific to trade name, the single dose and unit, the frequency  and route of 
administration, the start and discontinuation date and the reason for therapy.
[ADDRESS_867787] make every  effort to determine the primary  reason for a 
patient's wit hdrawal from the study  and reco rd this information on the CRF.
[COMPANY_001] Confidential Page 40
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
The Investigator should discontinue study  treatment for a given patient or withdraw the 
patient from study  if on balance they believe that continuation would be detrimental to the 
patient's well- being. Under the following circumstances, individual study  treatment must be 
discontinued and the patient monitored until resolution of the reason for discontinuation 
according to the Investigator's discretion:
A reproducible and persistent (confirmed on repeat assessment within 24 –48 hr) increase 
in serum creatinine ≥0.3 mg/dL from baseline. Any  increases in serum creatinine 
≥0.3 mg/dL based on local laboratory  assessments should trigger repeat assessments of 
serum creatinine until event resolution (e.g. serum creatinine within 10% of baseline) or 
event stabilization. Baseline is defined as the average of all available pre -dose 
measurements. 
Systolic blood pressure <90 mm Hg (must be confirmed on repeat measureme nt after 
30minutes) or sy mptomatic h ypotension
Any protocol deviation (e.g. use of an ACE inhibitor) that results in a significant risk to 
the patient's safet y
7.[ADDRESS_867788] to follow -up
For subjects whose status is unclear because they  fail to appear for study  visits without stating 
anintention to discontinue or withdraw, the investigator should show "due diligence" by 
[CONTACT_762], e.g. dates of 
telephone calls, registered letters, etc. A subject should not be formally  consider ed lost to 
follow -up until his/her scheduled end of stud y visit would have occurred.
7.[ADDRESS_867789] and does not allow anal ysis of already  obtained biologic material.
[COMPANY_001] Confidential Page 41
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
If a subject withdraws consent, the investigator must make every effort to determine the 
primary  reason for this decision and record this information. Study  treatment must be 
discontinued and no further assessments conducted. All biological material that has not been 
analyzed at the time of withdrawal must not be used. Further attempts to contact [CONTACT_647927] y findings require communicating or follow -up.
7.4 Stud y Stoppi[INVESTIGATOR_647911] a full safet y review:
1 or more stud y-drug related S[LOCATION_003]R is reported
2 patients experience a sy stolic blood pressure <90 mm Hg that is persistent (>8 hours) 
and sy mptomatic and suspected to be related to the study  drug
3 patients experience a doubling of their baseline serum creatinine (based on local 
laboratory  assessments) that is suspected to be related to the study  drug. Baseline is 
defined as the average of all available pre -dose measurements.
[ADDRESS_867790]’s interests.
The investigator will be responsible for informing IRBs/IECs of the early termination of the 
trial.
[COMPANY_001] Confidential Page 42
Amended Pro tocol Version v04 (Clean ) Protocol No. CLHW 090X2102
8 Procedures and assessments
Table 8-1 Assessment Schedule, Part 1
Epoch Screening Treatment
Study  Phase Screening Baseline Treatment
Visit numbers (internal use only ) 1 2 3 101 102 103 104 105 106 107 108
Visit name (internal use only )ScreeningDay 
-2Day -1 Day 1Day 2Day 3 Day 4 Day 5Day 6Day 7 Day 8
Study  Day(s) -28 to -2 -2 -1 1 2 3 4 5 6 7 8
Time (post -dose) - - 0h 4h 8h 12h - - - 0h 1h 2h 3h 4h 8h 12h - - - 0h 1h 2h 3h 4h 8h 12h
Informed consent X
Inclusion / Exclusion criteria X X
Study drug administration X X X X X X X X
Subjects domiciled X
Medical history/current medical conditions X
Demography X
Body height X
Body weight X
Vital Signs X X X X X X X X X X X
Physical examination X X
Hepatitis and HIV Screen X
Alcohol Test, Drug Screen, and Cotinine 
TestX
ECG evaluation X X
Hematology X X X
[COMPANY_001] Confidential Page 43
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Epoch Screening Treatment
Study Phase Screening Baseline Treatment
Visit numbers (internal use only) 1 2 3 101 102 103 104 105 106 107 108
Visit name (internal use only) ScreeningDay 
-2Day -1 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8
Study Day(s) -28 to -2 -2 -1 1 2 3 4 5 6 7 8
T i m e  ( p o s t - d o s e ) - - 0 h4 h8 h1 2 h - - - 0 h1 h2 h3 h4 h8 h1 2 h - - - 0 h1 h2 h3 h4 h8 h1 2 h
Blood chemistry2X X XXX X XXX X
Urinalysis X X X X 
Urine albumin:creatinine ratio3X X X
X X 
X X
XXX X X X XX X X X XX X
XX X X XX X X XX X
XXXXXX X X XXXXXX X
X
X X X
Columbia-Suicide Severity Rating Scale X X
Adverse events X
Concomitant therapi[INVESTIGATOR_014] X
Phase/Study completion information X Corporate Confidential Information
[COMPANY_001] Confidential Page 44
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Epoch Treatment
Study Phase Treatment Study Completion /Early termination 30 day Safety Follow up call
Visit numbers (internal use only) 109 110 111 112 113 114 199 n/a
Visit name (internal use only)Day 
9Day 
10Day 
11Day 12Day 
13Day 
14End of study
Study Day(s) 9 10 11 12 13 1421
-1 +251
T i m e  ( p o s t - d o s e )- - - 0 h1 h2 h3 h4 h8 h 1 2 h - - -
Informed consent
Inclusion / Exclusion criteria
Study drug administration X X X X
Subjects domiciled X
Medical history/current medical 
conditions
Demography
Body height
Body weight
Vital Signs X X X X XX X
Physical examination X X
Hepatitis and HIV Screen
Alcohol Test, Drug Screen, and 
Cotinine Test
ECG evaluation X 
Hematology X X X
Blood chemistry2XXXX XX X
Urinalysis X X X
X X X
X X 
X X X
X X XXX X
X XXX X
PK blood collection6X XXXXXXX XCorporate Confidential 
Information
[COMPANY_001] Confidential Page 45
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Epoch Treatment
Study Phase Treatment Study Completion /Early termination 30 day Safety Follow up call
Visit numbers (internal use only) 109 110 111 112 113 114 199 n/a
Visit name (internal use only)Day 
9Day 
10Day 
11Day 12Day 
13Day 
14End of study
Study Day(s) 9 10 11 12 13 1421
-1 +251
T i m e  ( p o s t - d o s e )- - - 0 h1 h2 h3 h4 h8 h 1 2 h - - -
X
Columbia-Suicide Severity Rating 
ScaleX X
Adverse events X X
Concomitant therapi[INVESTIGATOR_014] X
Phase/Study completion 
informationX X
1Visit structure given for internal programming purpose only
2including Cystatin C
3First morning void
6PK blood samples obtained at 0h will be pre-dose samples on Days 4, 8 and 12
7Pre-dose
9Assessments on Study Days 1-3, 5-7, and 9-11 should be done pre-dose.Corporate Confidential 
Information
Corporate Confidential Information
Corporate Confidential Information
[COMPANY_001] Confidential Page 46
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
Table 8-2 Assessment schedule Part 2, Patients 1 -16 
Epoch Screening Treatment
Study  Phase Screening BaselineTreatment
Study  Completion30 
Day 
safety  
follow 
up 
call
Visit Numbers1V1 V22V3 V3.1 V3.2 V3.3 V3.4 V3.5 V43V5 V6 V7 V777 n/a
Visit numbers 
(internal use 
only) 1 4 201201.1 201.2 201.3 201.4 201.5
202 203 204 205 299
Visit name 
(internal use 
only)Screening Day -1 Day 1Day 
2Day 
3Day  4 Day 
5Day 
6 Day 7Day 
14Day 
21Day 28 End of study
Study  Day (s) -28 to -4 -1 12 3 4 5 6 7
-1 +114
-1 +121
-1 +128
-1 +035
-1 +265
Time (post -dose) - 0h - 0h 1h 2h 3h 4h 8h 12h - - - 0h 1h 2h 3h 4h 8h -
Informed consent X
Inclusion / 
Exclusion criteriaX X
Dose 
administration4X
Domicile X
Medical 
history/current 
medical 
conditionsX
Demography X
Body height X
Body weight X
Hepatitis and HIV 
ScreenX
Vital Signs X X X X X X X X X X X X X
Physical X X X X
[COMPANY_001] Confidential Page 47
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Epoch Screening Treatment
Study Phase Screening BaselineTreatment
Study Completion30 
Day 
safety 
follow 
up 
call
Visit Numbers1V1 V22V3 V3.1 V3.2 V3.3 V3.4 V3.5 V43V5 V6 V7 V777 n/a
Visit numbers 
(internal use 
only) 1 4 201201.1 201.2 201.3 201.4 201.5
202 203 204 205 299
Visit name 
(internal use 
only)Screening Day -1 Day 1Day 
2Day 
3Day  4 Day 
5Day 
6D a y  7Day 
14Day 
21Day 28 End of study
Study Day(s) -28 to -4 -1 12 345 6 7
-1 +114
-1 +121
-1 +128
-1 +035
-1 +265
Time (post-dose) - 0h - 0h 1h 2h 3h 4h 8h 12h - - - 0h 1h 2h 3h 4h 8h -
examination
Alcohol Test, 
Drug Screen, and 
Cotinine TestX
ECG evaluation X X 
Hematology X X X X X
Blood chemistry5XX X X X X X X X X X X X
Urinalysis X X X X X X X X X X X X X
XX X X X X X X X X X X X
X X X
XX X X X X X
XX X XCorporate
Confidential
Information
[COMPANY_001] Confidential Page 48
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Epoch Screening Treatment
Study Phase Screening BaselineTreatment
Study Completion30 
Day 
safety 
follow 
up 
call
Visit Numbers1V1 V22V3 V3.1 V3.2 V3.3 V3.4 V3.5 V43V5 V6 V7 V777 n/a
Visit numbers 
(internal use 
only) 1 4 201201.1 201.2 201.3 201.4 201.5
202 203 204 205 299
Visit name 
(internal use 
only)Screening Day -1 Day 1Day 
2Day 
3Day  4 Day 
5Day 
6D a y  7Day 
14Day 
21Day 28 End of study
Study Day(s) -28 to -4 -1 12 345 6 7
-1 +114
-1 +121
-1 +128
-1 +035
-1 +265
Time (post-dose) - 0h - 0h 1h 2h 3h 4h 8h 12h - - - 0h 1h 2h 3h 4h 8h -
PK blood 
collection9XXXXXX X XX X X XXXXXX
Adverse eventsX
Columbia-Suicide 
Severity Rating 
ScaleXX X X X
Concomitant 
Medication X
Arterial spin 
labeling MRI10 X X
Phase/Study 
completion 
informationX 
X
1Visit structure given for internal programming purpose only
2MRI can be done within 2 days prior to the baseline visit
3MRI can be conducted within a day +/- of the Day 7 visit
4Patient is expected to take the drug every day for 4 weeks. 
Corporate Confidential 
Information
[COMPANY_001] Confidential Page 49
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Corporate Confidential Information
[COMPANY_001] Confidential Page 50
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Table 8-3 Assessment Schedule, Part 2 Patients 17 to 72, approximately 
Epoch Screening Treatment
Study Phase Screening Baseline Treatment Study Completion30 Day safety 
follow up call
Visit Numbers1V1 V22V3 V43V5 V6 V7 V777 n/a
Visit numbers (internal use only) 1 4 201 202 203 204 205 299
Visit name (internal use only) Screening Day -1 Day 1 Day 7 Day 14 Day 21 Day 28 End of study
Study Day(s) -28 to -4 -1 17
-1 +114
-1 +121
-1 +128
-1 +035
-1 +265
T i m e  ( p o s t - d o s e ) - 0 h - - - - 0 h1 h2 h3 h4 h8 h -
Informed consent X
Inclusion / Exclusion criteria X X
Dose administration4X
Medical history/current medical conditions X
Demography X
Body height X
Body weight X
Hepatitis and HIV Screen X
V i t a l  S i g n s X X XXXX X X
Physical examination X X X X
Alcohol Test, Drug Screen, and Cotinine Test X
ECG evaluation X X 
Hematology X X X X X
Blood chemistry5X X XXXX X X
Urinalysis X X X X X X X X
X X XXXX X X
X X X
XX X X X X X
XX X X
PK blood collection9X X X XXXXXX
Adverse events XXCorporate Confidential Information
[COMPANY_001] Confidential Page 51
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Epoch Screening Treatment
Study Phase Screening Baseline Treatment Study Completion30 Day safety 
follow up call
Visit Numbers1V1 V22V3 V43V5 V6 V7 V777 n/a
Visit numbers (internal use only) 1 4 201 202 203 204 205 299
Visit name (internal use only) Screening Day -1 Day 1 Day 7 Day 14 Day 21 Day 28 End of study
Study Day(s) -28 to -4 -1 17
-1 +114
-1 +121
-1 +128
-1 +035
-1 +265
T i m e  ( p o s t - d o s e ) - 0 h - - - - 0 h1 h2 h3 h4 h8 h -
Columbia-Suicide Severity Rating Scale X X X X X
Concomitant therapi[INVESTIGATOR_014] X
Arterial spin labeling MRI10X X
Phase/Study completion information X X
1Visit structure given for internal programming purpose only
2MRI can be done within 2 days prior to the baseline visit
3MRI can be conducted within a day +/- of the Day 7 visit
4Patient is expected to take the drug every day for 4 weeks  Corporate Confidential Information
[COMPANY_001] Confidential Page 52
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
8.1 Informed consent procedures
Eligible subjects may only be included in the study  after providing written (witnessed, where 
required b y law or regulation), I RB/IEC -approved i nformed consent.
Informed consent must be obtained before conducting any study -specific procedures (i.e. all 
of the procedures described in the protocol). The process of obtaining informed consent 
should be documented in the subject source documents.
The date of signing of informed consent (and withdrawal, if later withdrawn) should be 
documented in the CRF.
[COMPANY_001] will provide to investigators a proposed informed consent form that complies with 
the ICH GCP guideline and regulatory  requirements and is considered appropriate for this 
study . Any changes to the proposed consent form suggested by [CONTACT_275426] I RB/IEC.
Pregnancy  outcomes must be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.
A copy  of the approved version of all consent forms must be provided to the [COMPANY_001] monitor 
after IRB/IEC approval.
8.[ADDRESS_867791] d emographics/other baseline characteristics
Subject demographic and baseline characteristic data will be collected on all subjects.
Relevant medical history /current medical conditions data includes data until signature [CONTACT_86220]. Where possible, diagnoses and not sy mptoms will be recorded.
Investigators have the discretion to record abnormal test findings on the medical history  CRF 
whenever in their judgment, the test abnormality  occurred prior to the informed consent 
signature.
8.3 Efficacy  / Pharmaco dynamics
Efficacy  is not m easured in this clinical study .
8.4 Safet y
Safet y assessments are specified below; methods for assessment and recording are specified in 
the Site Operations Manual, with the Assessment Schedule detailing when each assessment is 
to be performed.
8.4.1 Physical examination
A complete physical examination will include the examination of general appearance, skin, 
neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, 
extremities, vascular and neurological. If indicated based on medical history  and/or sy mptoms, 
rectal, external genitalia, breast, and/or pelvic exams may be performed .
[COMPANY_001] Confidential Page 53
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
Information for all physical examinations should be included in the source documents and 
will not be transferred to the sponsor as part of the study  anal ysis. Significant findings that are 
present prior to informed consent are included in the Relevant Medical History  section of the 
source documents. Significant findings observed after informed consent signature [CONTACT_275437] y recorded on the Adverse Event 
eCRF section.
8.4.2 Vital signs
Body temperature
Blood pressure (BP) 
Pulse 
8.4.3 Height and weight
Height
Body weight
Body mass index (BMI) will be calculated (Body weight (kg) / [Height (m)]2)
8.4.[ADDRESS_867792] be reported and discussed with [COMPANY_001] personnel. The results should be 
evaluated for criteria defining an adverse event and reported as such if the criteria are met. 
Repeated evaluations are mandatory  until normalization of the result(s) or until the change is 
no longer clinicall y relevant. In case of doubt, [COMPANY_001] personnel should again be contact[INVESTIGATOR_530].
A central laboratory  will be used for analysis of all specimens collected. For the purposes of 
monitoring, a separate sample will be obtained for serum creatinine and dipstick urine testing 
at a local laboratory  and those results will be entered into the eCRF. Details on the collection, 
shipment of samples and reporting of results by [CONTACT_647928] t he laboratory  manual.
Hematology
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential and 
platelet count will be measured.
Clinical chemistry
Blood samples for clinical chemistry  should be collected early  morning after an overnight fast 
of at least [ADDRESS_867793], ALT, aPTT (activated partial thromboplastin time), PT/INR, CK, 
glucose, total cholesterol, trigly cerides. If the total bilirubin concentration is increased above 
1.[ADDRESS_867794] reacting bilirubin should be 
differentiated.
[COMPANY_001] Confidential Page 54
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
In Part 1, LFTs (total bilirubin, AST, ALT, GGT, alkaline phosphatase) and coagulation tests 
(aPTT, PT/INR) will be included as part of the chemistry panel on screening, Days -1, 4, 8, 12, 14, and end of study visits.
Urinalysis
Urine samples for urinalysis,  
 
 
 
will be requested while they are at the clinic.
Urine test by [CONTACT_5230] e.g. Combur9: leucocytes, nitrite, pH, protein, glucose, ketones, 
urobilinogen, bilirubin, blood/ hemoglobin
If the dipstick result is positive for protein, nitrite, leucocytes and/or blood, the sample will be 
sent for microscopic analysis of WBC, RBC and casts. If casts are noted, the type is to be specified on the relevant CRF page.
8.4.5 Electrocardiogram (ECG)
Each ECG tracing should be labeled with study number, subject initials, subject number, date 
and time, be appropriately signed and dated to confirm review and filed in the study site source documents. For any ECGs with subject safety concerns, two additional ECGs should 
be performed to confirm the safety finding. Clinically significant ECG findings prior to 
dosing with investigational treatment must be discussed with the sponsor. 
Additional details of procedures relating to the ECG collection and reporting will be 
contained in the site operations manual.
For all studies:PR interval, QRS duration, heart rate, RR, QT, QTcThe Fridericia QT correction formula (QTcF) should be used for clinical decisions. 
8.4.6 Pregnancy and assessments of fertility
Not applicable. Only women of non-childbearing potential will be included in this study.Corporate Confidential Information
Corporate Confidential Information
[COMPANY_001] Confidential Page 55
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
8.5 Pharmacokinetics
PK samples will be collected at the time-points defined in the Assessment schedule.
Further details on sample collection, numbering, processing and shipment can be found in the
Site Operations Manual. LHW090 and its active metabolite LHV527 will be determined in plasma using a validated LC-MS/MS method with the Lower Limit of Quantification (LLOQ) 
of 5.00 ng/mL. Untreated samples (placebo) will not be analyzed unless deemed necessary. Concentrations will be expressed in ng per mL units. Concentrations below the LLOQ will be 
reported as “zero”and missing data will be labeled as such in the Bioanalytical Data 
Report.  
 
 
For standard pharmacokinetic abbreviations and definitions see the list provided at the
beginning of this protocol. The following pharmacokinetic parameters will be determined 
using the actual recorded sampling times and non-compartmental method(s) with Phoenix WinNonlin (Version 6.2 or higher): Cmax, Tmax, AUClast, AUC0-t, AUCtau from the plasma concentration-time data. Other pharmacokinetic parameters may be determined, if relevant.  
8.6 Other assessmentsCorporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
[COMPANY_001] Confidential Page 56
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
9 Safety monitoring
9.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and 
unintended sign [including abnormal laboratory findi ngs], symptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study. Therefore, an AE may or may not be temporally or causally associated with the use of a 
medicinal (investigational) product.
The occurrence of adverse events should be sought by [CONTACT_105]-directive questioning of the subject 
at each visit during the study. Adve rse events also may be detected when they are volunteered 
by [CONTACT_144970], laboratory test, or other assessments.
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
!they induce clinical signs or symptoms,
!they are considered clinically significant,
!they require therapy.
Clinically significant abnormal laboratory values or test results should be identified through a 
review of values outside of normal ranges/clinically notable ranges, significant changes from baseline or the previous visit, or values which are considered to be non-typi[INVESTIGATOR_647912]. Investigators have the respon sibility for managing th e safety of individual 
subject and identifying adverse events. Alert ranges for liver related events are included in Section 9.[ADDRESS_867795] be recorded on the Adverse Events CRF for subjects that pass screening 
and enter into the study. The adverse events should be reported according to the signs, symptoms or diagnosis associated with them, and accompanied by [CONTACT_6644]:
1. the severity grade
!mild: usually transient in nature and generally not interfering with normal activities
!moderate: sufficiently discomforting to interfere with normal activitiesCorporate Confidential Information
[COMPANY_001] Confidential Page 57
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
severe: prevents normal activities
2.its relationship to the study  treatment ( no/yes),
3. its duration (start and end dates) or if the event is ongoing an outcome of not 
recovered/not resolved should be reported.
4. whether it constitutes a serious adverse event (SAE) See Section 9.2 for definition of SAE
5.action taken regarding [study /investigational] treatment(select as appropriate).
All adverse events should be treated appropriately . Treatment may include one or more of the 
following:
no action taken (i.e. further observation only )
study  treatment dosage adjusted/temporarily  interrupted
study  treatment permanently  discontinued due to this adverse event
concomitant medication given
non-drug therap y given
subject hospi[INVESTIGATOR_057]/subject’s hospi[INVESTIGATOR_18533]
6.its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, 
recovered/resolved with sequelae; fatal; or unknown)
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequently , 
ifnecessary ) of any changes in severit y, the suspected relationship to the study  drug, the 
interventions required to treat it, and the outcome.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator Brochure (IB) or Core Data Sheet (for marketed drugs) or will be 
communicated between IB updates in the form of Investigator Notifications. This information 
will be included in the subject informed consent and should be discussed with the subject 
during the stud y as needed.
The investigator should also instruct each subject to report any  new adverse event (beyond the 
protocol observation period) that the subject, or the subject’s personal physician, believes 
might reasonabl y be related to study  treatment. This information should be recorded in the 
investigator’s source documents; however, if the AE meets the criteria of an SAE, it must be 
reported to [COMPANY_001].
9.2 Serious adverse event reporting
9.2.1 Definition of SA E
An SAE is defined as any adverse event (appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s) or medical conditions(s) which meets any one of the 
following criteria:
is fatal or life -threatening
results in persistent or significant disability /incapacity
constitutes a con genital anomaly /birth defect
[COMPANY_001] Confidential Page 58
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]: 
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition 
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study   and has not worsened since the start of study  drug
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]
social reasons and respi[INVESTIGATOR_5316]’s 
general condition
is medically  significant, i.e. defined as an event that jeopardizes the subject or may  require 
medical or surgical intervention.
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if more sever e.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
Medical and scientific judgment should be exercised in deciding whether other situations 
should be considered serious reactions, such as important medical events that might not be 
immediately  life threatening or result in death or hospi[INVESTIGATOR_647913]. 
Examples of such events are intensive treatment in an emergency  room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_50069].
All AEs (serious and non-serious) are captured on the CRF, SAEs also require individual 
reporting to DS&E as per Section 9.2.[ADDRESS_867796] be 
submitted within 24 hours of the investigator receiving the follow -up information. An SAE 
that is considered completely  unrelated to a previously  reported one should be reported 
separately  as a new ev ent.
[COMPANY_001] Confidential Page 59
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
Follow -up information provided should describe whether the event has resolved or continues, 
if and how it was treated, whether the treatment code was broken or not and whether the 
subject continued or withdrew from study  participation. Each re-occurr ence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the investigational treatment a Drug Safet y 
and Epi[INVESTIGATOR_351956] y require further information from the 
investigator for Health Authority  reporting. [COMPANY_001] may need to issue an Investigator 
Notification (IN) to inform all investigators involved in any study with the same 
investigational treatment that this SAE has been reported. Suspected Unexpected Serious 
Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to the competent authorities and 
relevant ethic s committees in accordance with EU Guidance 2011/C 172/[ADDRESS_867797] safety  and enhance reliability  in determining the hepatotoxic potential of an 
investi gational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.
The following two categories of abnormalities / adverse events have to be considered during 
the course of the study :
Liver laboratory  triggers, which will require repeated assessments of the abnormal 
laboratory  parameter
Liver events, which will require close observation, follow- up monitoring and completion 
of the standard base liver CRF pages
Please refer to Table 9-1and Table 9-2for complete definitions of liver laboratory  triggers 
and liver events.
Every  liver laboratory  trigger or liver event should be followed up by [CONTACT_647929], as summarized below and detailed in in Table 9-2.
For the liver laboratory  trigger:
Repeating the LFT within the next week to confirm elevation.
These LFT repeats should be performed using the central laboratory  if possible. If this is not 
possible, then the repeats can be performed at a local laboratory  to monitor the safet y of the 
patient. Repeats laboratory  should then be performed at central laboratory as soon as possible. 
If a liver event is subsequently  reported, any local LFTs previousl y conducted that are 
associated with this event should be reported on the L iver CRF pages.
If the elevation is confirmed, close observation of the patient will be initiate d, including 
consideration of treatment interruption if deemed appropriate.
[COMPANY_001] Confidential Page 60
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
For the liver events:
Repeating the LFT to confirm elevation as appropriate
Discontinuation of the investigational drug (refer to Section 7.1 , if appropriate
Hospi[INVESTIGATOR_131539]
A causalit y assessment of the liver event via exclusion of alternative causes (e.g. disease, 
co-medications)
An investigation of the liver event which needs to be followed until resolution.
These investigations can include serology  tests, imaging and pathology  assessments, 
hepatologist’s consultancy , based on investigator’s discretion. All follow -up information, and 
the procedures performed should be recorded as appropriate in the CRF, including the liver 
event overview CRF pages.
Table 9-1 Liver Event and Laboratory  Trigger Definitions
Definition/ thres hold
Liver laboratory 
triggers [ADDRESS_867798] < ALT / AST £ [ADDRESS_867799]
 1.[ADDRESS_867800] < TBL £ [ADDRESS_867801]
Liver events ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone pathology)
TBL > 2 × ULN (in the absence of known Gilbert syndrome)
ALT or AST > 3 × ULN and INR > 1.5
Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN and TBL > 2 × 
ULN [mainly conjugated fraction] without notable increase in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × ULN accompanied by (general) malaise, fatigue, abdominal 
pain, nausea, or vomiting, or rash with eosinophilia
Any adverse event potentially indicative of a liver toxicity *
[COMPANY_001] Confidential Page 61
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
Table 9-2 Follo w Up Requirements for Liver Events and Laboratory  Triggers
Criteria Actions required Follow -up monitoring
Potential Hy’s Law caseaDiscontinue the study drug 
immediately
Hospi[INVESTIGATOR_18552], if clinically 
appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion) 
ALT or AST
> 8 × ULN Discontinue the study drug 
immediately
Hospi[INVESTIGATOR_6547]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
> 3 × ULN and INR > 1.5 Discontinue the study drug 
immediately
Hospi[INVESTIGATOR_18552], if clinically 
appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
> 5 to ≤ 8 × ULN Repeat LFT within 48 hours
If elevation persists, continue 
follow -up monitoring
If elevation persists for more 
than 2 weeks , discontinue the 
study drug
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
> 3 × ULN accompanied 
by [CONTACT_18688]Discontinue the study drug 
immediately
Hospi[INVESTIGATOR_6547]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
> 3 to ≤ 5 × ULN
(patient is asy mptomatic)Repeat LFT within the next 
week
If elevation is confirmed, 
initiate close observation of 
the patientInvestigator discretion
Monitor LFT within 1 to 4 weeks
ALP (isolated)
> 2 × ULN (in the 
absence of known bone 
pathology)Repeat LFT within 48 hours
If elevation persists, establish 
causality
Complete liver CRFInvestigator discretion
Monitor LFT within 1 to 4 weeks or 
at next visit
TBL (isolated)
[COMPANY_001] Confidential Page 62
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
Criteria Actions required Follow -up monitoring
> 2 × ULN (in the 
absence of known Gilbert 
syndrome)Repeat LFT within 48 hours
If elevation persists, 
discontinue the study drug 
immediately
Hospi[INVESTIGATOR_6547]
Establ ish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
Test for hemoly sis (e.g. 
reticulocytes, haptoglobin, 
unconjugated [indirect] bilirubin)
> 1.5 to ≤ 2 × ULN
(patient is asymptomatic)Repeat LFT within the next 
week
If elevation is confirmed, 
initiate close observation of 
the patientInvestigator discretion
Monitor LFT within 1 to 4 weeks or 
at next visit
Jaundice Discontinue the study drug 
immediately
Hospi[INVESTIGATOR_18554]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
Any AE potentially 
indicative of a liver 
toxicity*Consider study drug 
interruption or discontinuation
Hospi[INVESTIGATOR_647914]
Establish causality
Complete liver CRFInvestigator discretion
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -
related conditions; the non- infectious hepatitis; the benign, malignant and unspecified liver neoplasms
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × ULN
b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia
cResolution is def ined as an outcome of one of the following: (1) return to baseline values, (2) stable 
values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after a 
maximum of 6 months, (4) liver transplantation, and (5) death.
9.4 Renal safety  monitoring
Renal events are defined as one of the following:
confirmed (on repeat measurement within 24 – 48 hr timeframe) increase in serum 
creatinine of ≥ 0.3 mg/dL compared to baseline 
The following two categories of abnormalities/adverse events have to be considered durin g 
the course of the study :
Serum creatinine triggers that will require follow up and repeat assessments of the 
abnormal laboratory  parameter
Urine dipstick triggers that will require follow up and repeat assessments of the
abnormal laboratory  parameter .
[COMPANY_001] Confidential Page 63
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
Please refer to Table 9 -3for specific renal alert criteria and actions.
Table 9-3 Specif ic Renal A lert Criteria and A ctions
Renal Event Actions
Serum creatinine increase
≥0.3 mg/dL compared to baselineConfirm ≥0.3 m g/dL increase in 24 -48 hr timeframe
Follow serum creatinine until event resolution or 
event stabilization
Serum creatinine inc rease  ³ 50 % compared 
to baseline*Follow up within 24 -48h if possible
Consider patient hospi[INVESTIGATOR_059] /specialized 
treatment
Albumin -or Protein -creatinine ratio increase ≥ 
2-fold
Albumin -creatinine ratio (ACR) ≥ 30 mg/g;
New dipstick proteinuria ≥ 1+
Protein -creatinine ratio (PCR ) ≥ 150 mg/g 
or >15 mg/mmolConfirm value after 24- 48h
Perform urine microscopy
Consider drug interruption / discontinuation
New dipstick glucosuria ≥ 1+ not due to 
diabetesBlood glucose (fasting)
Perform serum creatinine, AC R
New dipstick hematuria not due to trauma Urine sediment microscopy
Perform serum creatinine, ACR
Document contributing factors: co -medication, other co -morbid conditions, and additional diagnostic 
procedures performed in the CRF
Monitor patient regularly (frequency at investigator’s discretion) until one of the following:
Event resolution: (sCr within 10% of baseline or protein -creatinine ratio within 50% of baseline)
Event stabilization: sCr level with ±10% variability over last 6 months or prot ein-creatinine ratio 
stabilization at a new level with ±50% variability over last 6 months.
*Baseline is defined as the average of all pre -dose measurements from central laborator y 
assessments.
9.[ADDRESS_867802] be collected for the female partners of any males who 
took study  treatment in this study . 
Consent to report information regarding all pregnancy  outcomes should be obtained from the 
mother. The pregnancy  should be followed up to determine outcome, including spontaneous 
or voluntary  termination, details of the b irth, and the presence or absence of any  birth defects, 
congenital abnormalities, or maternal and/or newborn complications.
[COMPANY_001] Confidential Page 64
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
9.6 Prospective suicidality  assessment
The Columbia -Suicide Severit y Rating Scale (C-SSRS) is a questionnaire that prospectively 
assesse s Suicidal Ideation and Suicidal Behavior.
The C-SSRS, which uses a semi -structured interview to probe subject responses, will be 
administered by  [CONTACT_647930]. 
At the first study  visit, the“baseline/screening” version of the C-SSRS, will be administered. 
This version assesses Suicidal Ideation and Suicidal Behavior during the subject’s lifetime 
and during a predefined period. At subsequent visits, the “since last visit” version will be 
admi nistered.
If, at any time after screening and/or baseline, the score is “yes” on item 4 or item 5 of the 
Suicidal Ideation section of the C -SSRS or “y es” on any  item of the Suicidal Behavior section, 
the subject must be referred to a mental health care professional for further assessment and/or 
treatment. The decision on whether the study  treatment should be discontinued is to be taken 
by [CONTACT_348196].
In addition, all life-threatening events should be reported as SAEs. For example, if a subject 
answers “yes” to one of the questions in the Suicidal Behavior section, an SAE must be 
reported if the event was life-threatening. All events of “Non -Suicidal Self-Injurious 
Behav ior” (question also included in the Suicidal Behavior section) should be reported as AEs 
and assigned the appropriate severit y grade.
All SAEs relating to suicidal behavior should be reviewed by [CONTACT_647931] y Project Teams.
9.7 Early phas e safety  monitoring
The Investigator will monitor adverse events in an ongoing manner and inform the Sponsor of 
any clinically  relevant observations. Any required safet y reviews will be made jointly 
between medicall y qualified personnel representing the Sponsor and Investigator. 
Such evaluations may occur verball y, but the outcome and key discussion points will be 
summarized in writing (e-mail) and made available to both Sponsor and all Investigator(s). 
Criteria pertaining to stoppi[INVESTIGATOR_10098] /treatment or adapting the study  design are presented 
above.
When two or more clinical site(s) are participating in the clinical study, the Sponsor will 
advise the Investigator(s) at all sites in writing (e-mail) (and by [CONTACT_50106]) of any 
new, clinically relevant safet y information reported from another site during the conduct of 
the study  in a timel y manner.
[COMPANY_001] Confidential Page 65
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
10 Data revie w and database management
10.1 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and CRFs with the invest igators and their staff. 
During the study  [COMPANY_001] employ s several methods of ensuring protocol and GCP 
compliance and the quality /integrit y of the sites’ data. The monitor will visit the siteto check 
the completeness of subject records, the accuracy  of entries on the CRFs, the adherence to the 
protocol and to Good Clinical Practice, the progress of enrollment, and to ensure that study 
drug is being stored, dispensed, and accounted for accordi ng to specifications. Key study 
personnel must be available to assist the monitor during these visits.
The investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
subject's file. The investigator must also keep the original informed consent form signed by 
[CONTACT_423] (a signed copy  is given to the subject).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. [COMPANY_001] monitoring standar ds require full verification 
for the presence of informed consent, adherence to the eligibility  criteria, documentation of 
SAEs, and the recording of data that will be used for all primary  and safet y variables. 
Additional checks of the consistency  of the source data with the CRFs are performed 
according to the study -specific monitoring plan. No information in source documents about 
the identity  of the subjects will be disclosed.
10.[ADDRESS_867803] an external originating source (either written or electronic) with the CRF not 
being considered as source.
[COMPANY_001] Confidential Page 66
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
10.[ADDRESS_867804], which employ s the Anatomical Therapeutic Chemical classification system. 
Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulat ory activities (MedDRA) terminology .
Laboratory  samples will be processed locall y and/or centrall y as defined in the site operations 
manual and the results will be sent electronically  to [COMPANY_001] (or a designated CRO).
In Part 2 of the study , randomization codes and data in reference to dispensing of study  drug(s) 
to the subject and all IRT recorded dosage changes will be tracked using Interactive Response 
Technology  (IRT). The system will be supplied by a vendor, who will also manage the 
database. The data base will be sent electronically  to [COMPANY_001] (or a designated CRO).
At the conclusion of the study , the occurrence of any emergency  code breaks will be 
determined after return of all code break reports and unused drug supplies to [COMPANY_001] (Part 1 
only).
Each occurrence of a code break via IRT (Part 2 only) will be reported to the clinical team and 
monitor. The code break functionalit y will remain available until study  shut down or upon 
request of [COMPANY_001].
The occurrence of any protocol deviations will be determined. After these actions have been 
completed and the database has been declared to be complete and accurate , it will be locked 
and the treatment codes will be unblinded and made available for data analy sis. Any changes 
to the database after that time can only be made by [CONTACT_647932].
10.4 Data Monitoring Committee
Not required.
10.5 Adjudication Committee
Not required.
[COMPANY_001] Confidential Page 67
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
11 Data analy sis
11.1 Analysis sets
For all anal ysissets, subjects will be anal yzed according to the stud y treatment(s) received.
The safety  anal ysis set will include all subjects that received any  study  drug.
The PK analysis set will include all subjects with available PK data and no protocol 
deviations with relevant impact on PK data.
The PD analysis set will include all subjects with available PD data and no protocol 
deviations with relevant impact on PD data.
11.[ADDRESS_867805].
11.3 Treatments (study  drug, rescue medication, other concomitant 
therapi[INVESTIGATOR_014], compliance)
Data for study  drug administration (rescue medication) and concomitant therapi[INVESTIGATOR_647915], treatment group and subject.
11.4 Analysis of the primary  variable(s)
11.4.1 Variable(s)
The primary  safety variable will be the proportion of patients who develop a renal event. 
Thetwo parts of the study  will be analy zed separatel y. A renal event is defined as a 
reproducible increase in serum creatinine of ≥0.3 mg/dL from baseline confirmed on a repeat 
measurement within 24 to 48 hours. This threshold in serum creatinine was selected based on 
the published definitions of acute kidney injury (Mehta et al 2007 , Khwaja 2012) . 
Change from baseline will be evaluated and categorized as <0.3 mg/dL and ≥0.3 mg/dL . 
Theanalysis will be based on central laboratory  results. Baseline will be defined as the 
average of all available pre- dose measurements.
11.4.2 Statistical model, hypothesis, and method of analy sis
Part 1:
The purpose of the dose escalation in Part [ADDRESS_867806]-in-human study before the start of 
Part 2. Descriptive summary  statistics will be provided by [CONTACT_647933]/sampling 
time point, for change from baseline serum creatinine including the frequency  (n, %) of renal 
events <0.3 mg/dL and ≥ 0.3 mg/dL.
[COMPANY_001] Confidential Page 68
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Concentration response modeling may be carried out in Part [ADDRESS_867807], Part 2 of the study may not be initiated or a lower dose may be investigated.
Part 2:
For Part 2, a Chi-square test will be performed to compare the proportion of patients who 
develop a renal event in the LHW090 pooled active doses, LHW090 individual doses and 
placebo groups. This analysis will be stratified by [CONTACT_647921] (see Appendix 2 ). A logistic 
model with the baseline ARB dose and the baseline creatinine level as covariates may also be used. P-value and 95% CI of the difference in proportions will be presented. Descriptivesummary statistics will be provided by [CONTACT_10659]/sampling time point, for change from baseline serum creatinine including the frequency (n, %) of renal events <0.3 mg/dL and ≥ 0.3 mg/dL will be provided.
Historical data from internal [COMPANY_001] studies in a similar patient population may be used to 
supplement the information from patients on placebo in the current study.
Analyses stratified by [CONTACT_647934] (microalbuminuria or macroalbuminuria) and/or 
history of diabetes may also be conducted.
11.4.3 Handling of missing values/censoring/discontinuations
For the analysis of the proportion of patients with a renal events described in Section 11.4.[ADDRESS_867808] 2 weeks of treatment will be included in the denominator. For the analysis of change from baseline in serum creatinine described in Section 11.4.4 , all 
available data will be included and missing data will not be imputed (it will be estimated from the likelihood of the repeated measures model). Patients discontinued by [CONTACT_430587] a doubling of serum creatinine from baseline (based on local measurements) will be counted as having a renal event in the primary analysis regardless of the availability of a central serum creatinine value. In case more than 10% of patients drop out before [ADDRESS_867809], treatment by [CONTACT_647935] a continuous covariate. An unstructured covariance model will be used. Point estimates and the associated 95% confidence intervals for the difference between treatment and placebo at each visit will be provided.Corporate Confidential Information
[COMPANY_001] Confidential Page 69
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
11.5 Analysis of secondary and exploratory variables
11.5.1 Efficacy / Pharmacodynamics
The peak and mean AUC (AUC0-24h) of plas ma cGMP, Amount excreted (Ae) of Urine 
cGMP will be calculated and summarized by [CONTACT_647936]. Change from baseline and percent change from baseline of these variables will also be calculated and summarized.
11.5.2 Safety
[IP_ADDRESS] Vital signs
All vital signs data will be listed by [CONTACT_9524], treatment group, subject, and visit/time and if ranges 
are available abnormalities (and relevant orthostatic changes) will be flagged. Summary statistics will be provided by [CONTACT_9524], treatment group and visit/time.
[IP_ADDRESS] ECG evaluations
All ECG data will be listed by [CONTACT_9524], treatment group, subject and visit/time, abnormalities will 
be flagged. Summary statistics will be provided by [CONTACT_9524], treatment group and visit/time.
[IP_ADDRESS] Clinical laboratory evaluations
All laboratory data will be listed by [CONTACT_9524], treatment group, subject, and visit/time and if 
normal ranges are available abnormalities will be flagged. Summary statistics will be 
provided by [CONTACT_9524], treatment group and visit/time.
Change from baseline data will also be listed and summarized.
[IP_ADDRESS] Adverse events
All information obtained on adverse events will be displayed by [CONTACT_68592].
The number and percentage of subjects with adverse events will be tabulated by [CONTACT_50110] a breakdown by [CONTACT_647937]. A subject with multiple adverse events within a body system is only counted once towards the total of this body system.
[IP_ADDRESS] Other safety evaluations
Urine albumin creatinine ratio and Fractional excretion of phosphate in urine data will be 
listed by [CONTACT_9524], treatment group, subject and visit/time. Summary statistics will be provided by [CONTACT_9524], treatment group and visit/time. Change from baseline data will also be listed and summarized.Corporate Confidential Information
[COMPANY_001] Confidential Page 70
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
11.5.3 Pharmacokinetics
All drug concentrations below the lower limit of quantification (LLOQ) will be reported as 
“zero” and will be treated as zero for calculation of PK parameters.
LHW090/LHV527 plasma concentration data will be listed by [CONTACT_9524], treatment, subject, and
visit/sampling time point. Descriptive summary statistics will be provided by [CONTACT_647938]/sampling time point. Summary statistics will include mean (arithmetic and geometric), SD, CV (arithmetic and geometric), median, minimu m and maximum. An exception to this is 
Tmax where median, minimum and maximum will be presented. Concentrations below 
LLOQ will be treated as zero in summary statistics and for PK parameter calculations. A geometric mean will not be reported if the dataset includes zero values.
Pharmacokinetic parameters will be calculated as described in Section 8.[ADDRESS_867810].
Unbound PK concentration and PK parameter data will be listed and summarized for Part 1 as 
feasible.
Individual PK profiles and Arithmetic (SD) profile will be provide by [CONTACT_647936].
11.5.[ADDRESS_867811] a difference of 25% (increase from 3% on placebo to 28% on active) between the renal event rates on active (pooled doses) and placebo with 82% power and 10% type I error (1-sided test). 
11.7 Power for analysis of key secondary variables
Not applicable.Corporate Confidential Information
Corporate Confidential Information
[COMPANY_001] Confidential Page 71
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
12 Ethical considerations
12.1 Regulatory and ethical compliance
This clinical study was designed and shall be implemented and reported in accordance with 
the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US Code of Federal Regulations Title 21, and Japanese Ministry of Health, Labor, and Welfare), and with the ethical principles laid down in the Declaration of Helsinki.Corporate Confidential Information
[COMPANY_001] Confidential Page 72
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
12.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/inst itution should obtain approval/favorable opi[INVESTIGATOR_50074]/Independent Ethics Committee (IRB/IEC) for the trial 
protocol, written informed consent form, consent form updates, subject recruitment 
procedures (e.g. advertisements) and any other written information to be provided to subjects. 
Prior to study  start, the investigator is required to sign a protocol signature [CONTACT_16066]/her agreement to conduct the study  in accordance with these documents and all of the 
instruction s and procedures found in this protocol and to give access to all relevant data and 
records to [COMPANY_001] monitors, auditors, [COMPANY_001] Quality  Assurance representatives, designated 
agents of [COMPANY_001], IRBs/IECs, and regulatory  authorities as required. If an inspection of the 
clinical site is requested by a regulatory  authority , the investigator must inform [COMPANY_001] 
immediately  that this request has been made.
For multi- center trials, a Coordinating Investigator [INVESTIGATOR_442136] a reviewer and signatory for the clinical study  report.
12.3 Publication of study  protocol and results
[COMPANY_001] assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinical trials.gov. In addition, upon study  completion and 
finalization of the study  report the results of this trial will be either submitted for publication 
and/or posted in a publicly  accessible database of clinical trial results.
[ADDRESS_867812] be considered a protocol 
amendment, and unless such an amendment is agreed upon by [CONTACT_275436]/IEC/REB it cannot be implemented. All significant protocol deviations will be recorded 
and reported in the CSR.
13.[ADDRESS_867813] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC prior to 
implementation.
Only  amendments that are intended to eliminate an apparent immediate hazard to subjects 
may be implemented, provided the Health Authorities and the reviewing IRB/IEC are 
subsequently  notified b y protocol amendment.
[COMPANY_001] Confidential Page 73
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, the CTL 
should be informed and(serious) adverse event reporting requirements ( Section 9 ) followed 
as appropriate.
[COMPANY_001] Confidential Page 74
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
14 References
Bavishi C, Messerli FH, Kadosh B, et al (2015) Role of nepril ysin inhibitor combinations in 
hypertension: insight s from hy pertension and heart failure trials. Eur Heart J pii: ehv142 
(Epub ahead of print ).
Calhoun DA, Jones D, Textor S, et al (2008) Resistant hy pertension: diagnosis, evaluation, 
and treatment. A scientific statement from the American Heart Associatio n Professional 
Education Committee of the Council for High Blood Pressure Research. Hy pertension p. 
1403 -19.
Chobanian AV, Bakris GL, Black HR, et al (2003) National Heart, Lung, and Blood Institute 
Joint National Committee on Prevention, detection, evalua tion, and treatment of high blood 
pressure; National High Blood Pressure Education Program Coordinating Committee. The 
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure: the JNC 7 repo rt. JAMA 289:2560-72.
Gu J, Noe A, Chandra P, et al (2010) Pharmacokinetics and pharmacod ynamics of L CZ696, a 
novel dual -acting angiotensin receptor -nepril ysin inhibitor (ARNi). J Clin Pharmacol ;
50:401 -14.
James PA, Oparil S, Carter BL, et al (2014) 2014 evidence -based guideline for the 
management of high blood pressure in adults: report from the panel members appointed to the 
Eighth Joint National Committee (JNC 8). JAMA 311:507-20.
Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney  injur y. Nephron Clin 
Pract ;c179 -84.
Levey  AS, Coresh J, Greene T, et al (2006) Using standardized serum creatinine values in the 
modification of diet in renal disease stud y equation for estimating glomerular filtration rate. 
Ann Intern Med; 247-54.
Loghman -Adham M, Kiu Weber CI, Ciorciaro C, et al (2012) Detection and management of 
nephrotoxicity  during drug development. Expert Opin Drug Saf ; 581-96.
Mancia G, Fagard R, Narkiewicz K, et al (2013) ESH/ESC Guidelines for the management of 
arterial h ypertension. J Hy pertens ;31:1281-1357.
Mehta RL , Kellum JA, Shah SV, et al (2007) Acute Kidney  Injury  Network: report of an 
initiative to improve outcomes in acute kidney  injury . Crit Care ;R31.
Valderrama AL, Gillespie C, King SC, et al (2012) Vital Signs: Awareness and treatment of 
uncontrolled hy pertension among adults -[LOCATION_002], 2003- 2010 Morbidity  and Mortalit y 
Weekly  Report. 61(35):703-709.
Weber MA, Schiff irn EL, White WB, et al (2014) Clinical practice guidelines for the 
management of h ypertensi on in the communi ty. A Statement by  [CONTACT_647939] y of H ypertension. The Journal of Clinical 
Hypertension Vol 16 (1):14 -26.
[COMPANY_001] Confidential Page 75
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
15 Appendix 1:(Blinding table)
Time or Event
RoleRandomization 
list generatedTrt allocation 
& dosingSafety  event 
(single subject 
unblinded)IA & dose 
escalation
Subjects B B UI B
Site staff e.g. investigator and study 
nurseB B UI B
Unblinded site staff e.g. pharmacy staff B UI UI UI
Drug Supply and Randomization Office UI UI UI UI
Unblinded sponsor staff e.g. for drug 
re-supply, unblinded monitor, sample 
analyticsB UI UI UI
Statistician/statistical 
programmer/biomarker expertB B UI UI
Independent committees (e.g. DMC, 
internal stats analysis team) used for 
assessing interim resultsNA NA NA NA
All other sponsor staff not identified 
above (trial team, project team, 
management & decision boards, 
support functions)B B UI UI
IA Interim analyses
UIAllowed to be unblinded on individual patient level
BRemains blinded
At Database lock all roles can be unblinded
Subjects and investigator will remain blinded to study  treatme nt throughout the study 
(except in the case of a safet y event necessitating unblinding). The identity  of the treatments 
will be concealed by [CONTACT_29952], labeling, 
schedule of administration, appearance, and odor.
With the exception of unblinded site staff identified below, all site staff (including study 
investigator and study  nurse) will be blinded to study  treatment during treatment allocation 
and at the point of subject dosing but may be unblinded to the treatment assignment of an 
individual subject in case of a safet y event necessitating unblinding.
Unblinding a single subject for safet y reasons (necessary for subject management) will occur 
via an emergency  system in place at the site.
Unblinded site staff: Drug product will be supplied in bulk, so an unblinded pharmacist who is 
independent of the study team will be required in order to maintain the blind. This unblinded 
pharmacist will receive a randomization list or treatment allocation cards from Drug Suppl y 
Management with the appropriate treatment allocation numbers. Appropriate measures must 
be taken by [CONTACT_647940].
[COMPANY_001] Confidential Page 76
Amended Protocol Version v04 (Clean ) Protocol No. CLHW 090X2102
Unblinded sponsor staff: The following unblinded sponsor roles are required for this study :
Unblinded monitor
Unblinded sample anal yst (PK blood and urine)
Unblinded sample anal yst (biomarker XXX)
The unblinded monitor is required to review drug accountabil ity and allocation at site. 
Theunblinded monitor is not provided with a randomization list directly  but will be unblinded 
through review of source documentation compi[INVESTIGATOR_647916], which details 
treatment allocation to individual subjects. The unblinded monitor will also be able to review 
the treatment allocation cards/randomization list provided to the unblinded pharmacist. 
Thenames of the unblinded monitor(s) are detailed in the Monitoring Plan.
The sample analysts will receive a copy of the randomization schedule (via request to the 
Randomization Office) to facilitate analysis of the samples. The sample analy sts will provide 
the sample data to the team under blinded condi tions. Both the pharmacist and bioanaly st will 
keep this information confidential until clinical database lock.
The study  statistician will be able to access the randomization list for interim analyses and is 
allowed to share unblinded information with therest of the clinical team as appropriate for 
internal decision purposes, as outlined inthe blinding table above. For example, unblinded 
summaries and unblinded individual data can be shared with the team for planned and 
unplanned interim anal yses.
Study  programmers and other personnel involved in study  data anal ysis (e.g. biomarker expert) 
are allowed to access treatment assignment information for the purpose of conducting planned 
and unplanned interim analy ses.
The clinical trial team is allowed to share unblinded results with other sponsor staff 
(e.g. decision boards) as required for internal decision making on the study  or the project 
while the study  is ongoing.
[COMPANY_001] Confidential Page 77
Amended Protocol Version v04 (Clean) Protocol No. CLHW090X2102
Corporate Confidential Information